Aquestive Therapeutics (NASDAQ:AQST) Issues Quarterly Earnings Results

Aquestive Therapeutics (NASDAQ:AQST) announced its quarterly earnings data on Monday. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.01), Zacks reports. The business had revenue of $13.54 million for the quarter, compared to analyst estimates of $12.69 million. During the same quarter last year, the company posted ($0.03) earnings per share.

Aquestive Therapeutics Stock Up 1.8 %

Shares of Aquestive Therapeutics stock traded up $0.09 during trading on Thursday, reaching $5.16. The company’s stock had a trading volume of 682,012 shares, compared to its average volume of 1,750,238. Aquestive Therapeutics has a 52-week low of $1.55 and a 52-week high of $6.23. The company has a market cap of $469.87 million, a price-to-earnings ratio of -11.27 and a beta of 2.82. The firm’s 50-day moving average is $4.91 and its two-hundred day moving average is $3.83.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on AQST. Leerink Partners boosted their price target on shares of Aquestive Therapeutics from $12.00 to $13.00 and gave the company an “outperform” rating in a research report on Friday, October 25th. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Aquestive Therapeutics in a research report on Wednesday. Finally, JMP Securities reissued a “market outperform” rating and issued a $9.00 price target on shares of Aquestive Therapeutics in a research report on Tuesday, October 8th. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $8.83.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.